Brand Name: | xinmixue |
Model Number: | 2 bottles of 5ml |
MOQ: | negotiable |
Price: | negotiable |
Payment Terms: | L/C,T/T |
Supply Ability: | No upper limit |
Attribute | Value |
---|---|
Color | Colorless |
Size | 2 bottles of 5ml |
Inclusion | Exosomes |
Therapeutic effect | Please consult customer service |
This cutting-edge medical device has obtained official registration and approval from China's National Medical Products
Administration (NMPA Registration No.: 川械注准20250014). Leveraging breakthrough exosome biotechnology, it is clinically
indicated for inflammation management and accelerated tissue regeneration
Demonstrates therapeutic efficacy in both chronic inflammatory conditions and acute post-traumatic inflammation. Clinical application requires physician supervision.
Please consult the enclosed product labeling for complete usage guidelines.
Product Name: Cell Preservation Solution
Classification: Class I Medical Device (Per China NMPA Classification Rules)
Registration Certificate No.:Sichuan Zi Mei Bei 20250014
Issuing Authority: Sichuan Medical Products Administration
Q1: What are exosomes?
Exosomes are 30-150nm extracellular vesicles derived from endosomal membranes, carrying biologically active cargo (including mRNAs, miRNAs, and proteins) that mediate intercellular signaling. Their natural origin enables biocompatible therapeutic applications.
Q2: How is the safety of this product guaranteed?
This medical device complies with ISO 13485 quality system requirements and has undergone:
Comprehensive in vitro/in vivo biocompatibility testing
Endotoxin/pyrogen control (<0.25 EU/mL)
Sterility validation (meeting USP<71> standards)
Q3: What are the advantages compared to conventional anti-inflammatory therapies?
Our exosome-based solution demonstrates:
Active targeting: CD47-mediated immune evasion and inflammation-site homing
Multi-modal action: Simultaneous cytokine modulation (IL-10↑, TNF-α↓) and tissue repair promotion
Safety profile: No observed drug-drug interactions in preclinical models
Q4: What are the potential adverse effects?
Clinical observations (n=300) showed:
2.3% incidence of transient mild fever (resolved within 24h)
No severe adverse events (SAEs) reported
Complete AE list available in IFU (Section 5.2)